Matrix metalloproteinase 2 (MMP2) has been identified as a biomarker associated with BRAF mutations and is negatively correlated with survival in patients with BRAF-mutant melanoma, yet its application in clinical practice is limited [51]. Here, BRAF is linked to melanoma.